



Atty Dkt No.: 098810/0278741

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Warren, K., et al.

Art Unit : 1653

Serial No. : 09/813,383

Examiner : Sheridan Snedden

Filed : March 20, 2001

Title : PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS

RECEIVED

JUL 15 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

In response to the Action mailed May 15, 2002, Applicants elect Group I, consisting of claims 22-47, drawn to a method of treating multiple sclerosis by reducing free anti-myelin basic protein in patients suffering from MS by administration of a protein, classified in class 514, subclass 2.

Please apply any charges or credits to Deposit Account No. 03-3975. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (858) 509-4065.


07/12/2002 CNBUEA 00000090 09813383

01 FC:215
02 FC:203

55.00 OF
36.00 OF

Respectfully submitted,

Date: 7-2-02


Robert M. Bedgood, Ph.D.
Reg. No. 43,488

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130-1593
General Tel: (619) 234-5000
Facsimile: (858) 509-4010

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900



165345
Attorney Docket No. 098810/278741

RECEIVED

JUL 15 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: WARREN, K., et al.
Serial No.: 09/813,383
Filing Date: March 20, 2001
For: PEPTIDE SPECIFICITY OF
ANTI-MYELIN BASIC
PROTEIN AND THE
ADMINISTRATION OF
MYELIN BASIC PROTEIN
PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS

) Certificate of Mailing Under 37 CFR § 1.8

) I hereby certify that on the date indicated below, this
) paper and the attached papers are being delivered via
) U.S. First Class Mail, postage prepaid, addressed to:

) Assistant Commissioner for Patents
) Washington, DC 20231, on this date

) *Karyn F. Massie*
) Karyn F. Massie

) 7/2/02
) Date

TECH CENTER 1600/2900

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

COPY OF PAPERS
ORIGINALLY FILED

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing are the following:

1. Reply/Amendment/ Letter (in duplicate);
2. Response to Office Action mailed May 15, 2002; and
3. Return Postcard.

The Commissioner is hereby authorized to charge any fee, including any submitted herewith, if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: July 2, 2002

By *Robert M. Bedgood*
Robert M. Bedgood, Ph.D Reg. No. 43,488

11682 El Camino Real, Suite 200
San Diego, CA 92130-2593
Facsimile: (858) 509-4010
Direct Line: (858) 509-4065

RECEIVED

JUL 23 2002

I hereby certify that this correspondence and any paper referred to as being attached or enclosed) is being mailed via "First Class Mail" of the United States Postal Service on the date shown below in an envelope addressed to the Assistant Commissioner for Patents, U.S. Patent & Trademark Office, Washington, D.C. 20231

Dated: July 2, 2002

By: Karyn A. Massie
Karyn A. Massie

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Warren, K., et al.

Appn. No.: 09

813,383

Serial Code ↑

Serial No. ↑

Group Art Unit 1653

Examiner: Sheridan Snedden

Atty. Dkt. P 098810 0278741

M#

Client Ref

Filed: March 20, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

RECEIVED

JUL 15 2002

Appln. Title: PEPTIDE SPECIFICITY OR ANTI-MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE SCLEROSIS PATIENTS

Sir:

REPLY/AMENDMENT/LETTER

TECH CENTER 1600/2900

Date: July 2, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herewith by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☒ made previously
- For B & C
See Required
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
25	**minus 21	4	x \$18/\$9 =	+ \$36	103/203
2	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: June 15, 2002 <input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached			(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (4 mos) \$1,440/\$720 = (5 mos) \$1,960/\$980 =	+ \$55	115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8.			Extension Fee	+ \$55	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180	+ \$0	126
or if Rule 97(d) Request add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$740/370	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15.			TOTAL FEE =	\$91	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 098810 0278741

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

COPY OF PAPERS
ORIGINALLY FILED

11682 El Camino Real, Suite 200
San Diego, CA 92130-2092
Tel: (619) 234-5000

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robert M. Bedgood, Ph.D.

Sig: *Robert M. Bedgood*

Reg. No. 43,488

Fax: (858) 509-4010

Tel: (858) 509-4065

Atty/Sec: RMB/kfm

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

